Optipharm.CO.LTD (153710) - Cash Flow Conversion Efficiency

Latest as of December 2025: -0.016x

Based on the latest financial reports, Optipharm.CO.LTD (153710) has a cash flow conversion efficiency ratio of -0.016x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-408.70 Million ≈ $-276.97K USD) by net assets (₩25.40 Billion ≈ $17.21 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See net asset quality index of Optipharm.CO.LTD to measure how much of total assets are equity-financed.

Optipharm.CO.LTD - Cash Flow Conversion Efficiency Trend (2015–2025)

This chart illustrates how Optipharm.CO.LTD's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Optipharm.CO.LTD (153710) cash earnings ratio to evaluate the quality of earnings relative to operating cash generation.

Optipharm.CO.LTD Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Optipharm.CO.LTD ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Kodiak Copper Corp V:KDK	-0.019x
Tanami Gold NL AU:TAM	-0.106x
Lexibook Linguistic Electronic System SA PA:ALLEX	-0.217x
Ozderici Gayrimenkul Yatirim Ortakligi AS IS:OZGYO	0.006x
Mawana Sugars Limited NSE:MAWANASUG	0.839x
IGM Biosciences Inc NASDAQ:IGMS	-0.503x
ROK Resources Inc V:ROK	0.003x
Classic Scenic Bhd KLSE:7202	-0.022x

Annual Cash Flow Conversion Efficiency for Optipharm.CO.LTD (2015–2025)

The table below shows the annual cash flow conversion efficiency of Optipharm.CO.LTD from 2015 to 2025. For the full company profile with market capitalisation and key ratios, see Optipharm.CO.LTD stock valuation.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	₩25.40 Billion ≈ $17.21 Million	₩-1.55 Billion ≈ $-1.05 Million	-0.061x	-180.98%
2024-12-31	₩27.34 Billion ≈ $18.52 Million	₩-595.50 Million ≈ $-403.56K	-0.022x	+68.20%
2023-12-31	₩25.14 Billion ≈ $17.04 Million	₩-1.72 Billion ≈ $-1.17 Million	-0.069x	+18.34%
2022-12-31	₩29.01 Billion ≈ $19.66 Million	₩-2.43 Billion ≈ $-1.65 Million	-0.084x	-31.87%
2021-12-31	₩30.96 Billion ≈ $20.98 Million	₩-1.97 Billion ≈ $-1.33 Million	-0.064x	-32.95%
2020-12-31	₩33.78 Billion ≈ $22.89 Million	₩-1.62 Billion ≈ $-1.10 Million	-0.048x	-480.82%
2019-12-31	₩35.61 Billion ≈ $24.13 Million	₩447.47 Million ≈ $303.24K	0.013x	-62.99%
2018-12-31	₩35.44 Billion ≈ $24.02 Million	₩1.20 Billion ≈ $815.47K	0.034x	+66.43%
2017-12-31	₩12.79 Billion ≈ $8.67 Million	₩260.86 Million ≈ $176.78K	0.020x	-68.03%
2016-12-31	₩13.50 Billion ≈ $9.15 Million	₩861.36 Million ≈ $583.73K	0.064x	+136.47%
2015-12-31	₩4.30 Billion ≈ $2.91 Million	₩-751.51 Million ≈ $-509.29K	-0.175x	--

About Optipharm.CO.LTD

KQ:153710 Korea Diagnostics & Research

Market Cap

$46.48 Million

₩68.58 Billion KRW

Market Cap Rank

#22114 Global

#1341 in Korea

Share Price

₩4675.00

Change (1 day)

+1.30%

52-Week Range

₩4260.00 - ₩6200.00

All Time High

₩28900.00